Kymera Therapeutics, Inc. (KYMR)

Market Cap	2.73B
Revenue (ttm)	79.41M
Net Income (ttm)	-154.59M
Shares Out	61.36M
EPS (ttm)	-2.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	381,911
Open	44.70
Previous Close	44.04
Day's Range	43.12 - 45.32
52-Week Range	9.60 - 48.70
Beta	2.22
Analysts	Buy
Price Target	42.09 (-5.5%)
Earnings Date	Aug 1, 2024

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 21, 2020
• Employees: 187
• Stock Exchange: NASDAQ
• Ticker Symbol: KYMR

Financial Performance

In 2023, KYMR's revenue was $78.59 million, an increase of 67.84% compared to the previous year's $46.83 million. Losses were -$146.96 million, -5.07% less than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $42.09, which is a decrease of -5.50% from the latest price.

Price Target

$42.09

(-5.50% downside)

Analyst Consensus: Buy